CTLA4 and lung carcinoma: Similar results were seen in a recent report of patients with small cell lung cancer treated with PD-1 plus CTLA-4 blockade (Hellmann et al., 2018), suggesting the importance of TMB as biomarker for combination immunotherapy across lung cancers.